<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194675</url>
  </required_header>
  <id_info>
    <org_study_id>01166</org_study_id>
    <secondary_id>01166, 4-2280-V</secondary_id>
    <nct_id>NCT00194675</nct_id>
  </id_info>
  <brief_title>TRADE-Testosterone Replacement and Dutasteride Effectiveness</brief_title>
  <acronym>TRADE</acronym>
  <official_title>Testosterone Replacement and Dutasteride Effectiveness (TRADE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether the combination of the male
      hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large
      prostate glands can safely reduce the size of the prostate gland and symptoms of prostate
      enlargement (called benign prostatic hyperplasia [BPH]) compared to T treatment alone in men
      with low testosterone (called hypogonadism).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to determine whether correction of hypogonadism using a
      combination of testosterone and dutasteride spares subjects from increases in prostate size
      and symptoms of BPH which may be associated with T alone.

      We will also determine the effects of changes in serum T and dihydrotestosterone (DHT) on
      both the hormonal milieu and genetic program within the prostate gland itself. The technology
      employed will allow us to determine which genes are androgen responsive within each prostate
      tissue compartment. Together, these data may determine whether the combination of
      testosterone and dutasteride safely corrects the symptoms of BPH and hypogonadism and
      minimizes growth stimulus to the prostate at the genetic level. We will also assess the
      effects of the combination of T and dutasteride on cognitive function.

      This is a six-month, double-blind, randomized, placebo-controlled, single-site study of older
      hypogonadal men with mild to moderate BPH.

      Within each treatment group, a sub-group of subjects will undergo additional procedures as
      part of a Prostate Biopsy sub-study to obtain prostate tissue for hormonal and genetic
      analyses. Selection of subjects will be based on clinical indication and/or willingness to
      undergo prostate biopsies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of Testosterone Gel Alone or in Combination With Oral Dutasteride on Prostate Volume in Hypogonadal Men With Benign Prostatic Hyperplasia.</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum and Intraprostatic Hormone Levels: Prostate Specific Antigen (PSA)</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effects of T Alone or in Combination With Dutasteride on Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) in Hypogonadal Men With Benign Prostatic Hyperplasia. (International Prostate Symptom Score)</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <description>International Prostate Symptom Score to assess lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Minimum score = 0, maximum score = 35; mildly symptomatic score = 0-7; moderately symptomatic score = 8-19; severely symptomatic score = 20-35; no subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) in Hypogonadal Men (Uroflow)</measure>
    <time_frame>Baseline, 3-months, 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs and Symptoms Benign Prostatic Hyperplasia (BPH): Post-voiding Residual (PVR) Urinary Volume</measure>
    <time_frame>Baseline, 3-months, 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hormone Levels: Total Testosterone, Free Testosterone, and Dihydrotestosterone(DHT), Dehydroepiandrosterone(DHEA), and Androstenedione.</measure>
    <time_frame>Baseline, 3-months, 6-months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Testosterone gel + oral placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone 1% gel 7.5 topical daily + placebo dutasteride orally daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone gel + oral dutasteride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone 1% gel 7.5 topical daily + dutasteride 0.5 mg orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Dutasteride 0.5 mg orally daily</description>
    <arm_group_label>Testosterone gel + oral dutasteride</arm_group_label>
    <other_name>AndroGel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone gel</intervention_name>
    <description>Testosterone gel 7.5 g daily topical</description>
    <arm_group_label>Testosterone gel + oral placebo</arm_group_label>
    <arm_group_label>Testosterone gel + oral dutasteride</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo dutasteride</intervention_name>
    <description>placebo dutasteride orally daily</description>
    <arm_group_label>Testosterone gel + oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy older men 50 years old or older

          -  Hypogonadism; low testosterone (total T less than 280 ng/dL on one occasion or an
             average of equal to or less than 300 ng/dl on two occasions)

          -  Prostate volume equal to or more than 30 cc by prostate MRI

          -  Prostate Specific Antigen (PSA) equal to or more than 1.5 ng/mL and equal to or less
             than 10 ng/mL

          -  Subjects with a PSA greater than 4.0 ng/ml must have a negative prostate biopsy

          -  International Prostate Symptom Score (IPSS) greater than or equal to 8 and less than
             or equal to 20 at screening

          -  Comply with study procedures for the full 10 months

          -  No contraindications to MRI

        Subjects with symptomatic Benign Prostatic Hyperplasia (BPH) will be recruited from the
        Urology and General Internal Medicine Clinics at the VA Puget Sound Health Care System and
        University of Washington Medical Center in Seattle.

        Exclusion Criteria:

          -  A history of prostate or breast cancer

          -  Invasive therapy for BPH in the past

          -  History of acute urinary retention in the 3 months prior to screening

          -  Previous treatment with a 5 alpha-reductase inhibitor (finasteride or dutasteride)

          -  Medical therapy for BPH within the past month (alpha-blocker, phytotherapy)

          -  Use of androgenic or antiandrogenic drugs in the past year

          -  History or evidence of prostate cancer including suspicious DRE or history of
             high-grade PIN on prostate biopsy.

          -  Severe systemic illness (renal, liver, cardiac, lung disease, cancer, diabetes)

          -  Known untreated obstructive sleep apnea

          -  Hematocrit greater than 52

          -  Severe skin disease which may interfere with testosterone gel absorption

          -  Hypersensitivity to any of the drugs used in the study

          -  History of a bleeding disorder or need for chronic anticoagulation

          -  Participation in a drug study concurrently or in the last 90 days

          -  History or current evidence of drug or alcohol abuse within 12 mo.

          -  Weight more than 300 lbs.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alvin M Matsumoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>University of Washington</description>
  </link>
  <reference>
    <citation>Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003 Jan;51(1):101-15; discussion 115. Review.</citation>
    <PMID>12534854</PMID>
  </reference>
  <reference>
    <citation>Yialamas MA, Hayes FJ. Androgens and the ageing male and female. Best Pract Res Clin Endocrinol Metab. 2003 Jun;17(2):223-36. Review.</citation>
    <PMID>12787549</PMID>
  </reference>
  <reference>
    <citation>Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf). 2001 Apr;54(4):437-45.</citation>
    <PMID>11318778</PMID>
  </reference>
  <reference>
    <citation>Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf). 1994 Mar;40(3):341-9.</citation>
    <PMID>7514512</PMID>
  </reference>
  <reference>
    <citation>Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40.</citation>
    <PMID>4625049</PMID>
  </reference>
  <reference>
    <citation>Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003 May-Jun;24(3):299-311. Review.</citation>
    <PMID>12721204</PMID>
  </reference>
  <reference>
    <citation>Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996 Dec 18;276(23):1904-6.</citation>
    <PMID>8968017</PMID>
  </reference>
  <reference>
    <citation>Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001 Apr;47(1):52-8.</citation>
    <PMID>11304729</PMID>
  </reference>
  <reference>
    <citation>Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17;349(3):215-24. Epub 2003 Jun 24.</citation>
    <PMID>12824459</PMID>
  </reference>
  <reference>
    <citation>Monti S, Di Silverio F, Iraci R, Martini C, Lanzara S, Falasca P, Poggi M, Stigliano A, Sciarra F, Toscano V. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. J Clin Endocrinol Metab. 2001 Apr;86(4):1700-6.</citation>
    <PMID>11297606</PMID>
  </reference>
  <results_reference>
    <citation>Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol. 2011 Jul;186(1):191-7. doi: 10.1016/j.juro.2011.03.026. Epub 2011 May 14.</citation>
    <PMID>21575967</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>May 2, 2012</results_first_submitted>
  <results_first_submitted_qc>July 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2012</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Alvin M. Matsumoto, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>androgen deficiency</keyword>
  <keyword>testosterone</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>prostate</keyword>
  <keyword>BPH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the VA Puget Sound Health Care System, Seattle, WA. 102 men were screened and 53 were randomized.</recruitment_details>
      <pre_assignment_details>49 were excluded. 4 withdrew consent, 3 lost to follow-up, 42 for inclusion/exclusion criteria: 3 could not tolerate MRI, 3 were previously on testosterone therapy, 21 had prostate volume &lt;30cc, 12 had repeat serum testosterone &gt;280 ng/mL, and 3 had prostate cancer or prostate intraepithelial neoplasia at pre-treatment prostate biopsy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Testosterone Gel + Oral Placebo</title>
          <description>Testosterone 1% topical gel 7.5g daily + placebo dutasteride pill orally daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Testosterone Gel + Oral Dutasteride</title>
          <description>Testosterone 1% topical gel 7.5g daily + dutasteride 0.5 mg orally daily for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>lack of interest</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrew due to &quot;edgy&quot; feeling</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone Gel + Oral Placebo</title>
          <description>Testosterone 1% topical gel 7.5g daily + placebo dutasteride pill orally daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Testosterone Gel + Oral Dutasteride</title>
          <description>Testosterone 1% topical gel 7.5g daily + dutasteride 0.5 mg orally daily for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Between 50 and 82 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="8.0"/>
                    <measurement group_id="B2" value="63.6" spread="5.5"/>
                    <measurement group_id="B3" value="63.55" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of Testosterone Gel Alone or in Combination With Oral Dutasteride on Prostate Volume in Hypogonadal Men With Benign Prostatic Hyperplasia.</title>
        <time_frame>Baseline, Month 6</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Gel + Oral Placebo</title>
            <description>Testosterone 1% topical gel 7.5g daily + placebo dutasteride pill orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Gel + Oral Dutasteride</title>
            <description>Testosterone 1% topical gel 7.5g daily + dutasteride 0.5 mg orally daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Testosterone Gel Alone or in Combination With Oral Dutasteride on Prostate Volume in Hypogonadal Men With Benign Prostatic Hyperplasia.</title>
          <population>per protocol</population>
          <units>cubic centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="38.1"/>
                    <measurement group_id="O2" value="44.4" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" spread="38.7"/>
                    <measurement group_id="O2" value="38.6" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Intraprostatic Hormone Levels: Prostate Specific Antigen (PSA)</title>
        <time_frame>Baseline, Month 6</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Gel + Oral Placebo</title>
            <description>Testosterone 1% topical gel 7.5g daily + placebo dutasteride pill orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Gel + Oral Dutasteride</title>
            <description>Testosterone 1% topical gel 7.5g daily + dutasteride 0.5 mg orally daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Intraprostatic Hormone Levels: Prostate Specific Antigen (PSA)</title>
          <population>per protocol</population>
          <units>ng/ ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.9"/>
                    <measurement group_id="O2" value="2.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.9"/>
                    <measurement group_id="O2" value="1.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of T Alone or in Combination With Dutasteride on Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) in Hypogonadal Men With Benign Prostatic Hyperplasia. (International Prostate Symptom Score)</title>
        <description>International Prostate Symptom Score to assess lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Minimum score = 0, maximum score = 35; mildly symptomatic score = 0-7; moderately symptomatic score = 8-19; severely symptomatic score = 20-35; no subscales.</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Gel + Oral Placebo</title>
            <description>Testosterone 1% topical gel 7.5g daily + placebo dutasteride pill orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Gel + Oral Dutasteride</title>
            <description>Testosterone 1% topical gel 7.5g daily + dutasteride 0.5 mg orally daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of T Alone or in Combination With Dutasteride on Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) in Hypogonadal Men With Benign Prostatic Hyperplasia. (International Prostate Symptom Score)</title>
          <description>International Prostate Symptom Score to assess lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Minimum score = 0, maximum score = 35; mildly symptomatic score = 0-7; moderately symptomatic score = 8-19; severely symptomatic score = 20-35; no subscales.</description>
          <population>per protocol</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline IPSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="2.7"/>
                    <measurement group_id="O2" value="13.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3- IPSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="5.0"/>
                    <measurement group_id="O2" value="10.2" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 IPSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="5.2"/>
                    <measurement group_id="O2" value="10.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) in Hypogonadal Men (Uroflow)</title>
        <time_frame>Baseline, 3-months, 6-months</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Gel + Oral Placebo</title>
            <description>Testosterone 1% gel 7.5 daily + oral placebo dutasteride daily</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Gel + Oral Dutasteride</title>
            <description>Testosterone 1% gel 7.5 daily + dutasteride 0.5 mg po daily</description>
          </group>
        </group_list>
        <measure>
          <title>Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) in Hypogonadal Men (Uroflow)</title>
          <population>per protocol</population>
          <units>cc/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Uroflow, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="3.0"/>
                    <measurement group_id="O2" value="13.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uroflow after 3 months of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="3.4"/>
                    <measurement group_id="O2" value="13.2" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uroflow after 6 months of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="5.1"/>
                    <measurement group_id="O2" value="14.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Signs and Symptoms Benign Prostatic Hyperplasia (BPH): Post-voiding Residual (PVR) Urinary Volume</title>
        <time_frame>Baseline, 3-months, 6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Gel + Oral Placebo</title>
            <description>Testosterone 1% gel 7.5 daily + oral placebo dutasteride daily</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Gel + Oral Dutasteride</title>
            <description>Testosterone 1% gel 7.5 daily + dutasteride 0.5 mg po daily</description>
          </group>
        </group_list>
        <measure>
          <title>Signs and Symptoms Benign Prostatic Hyperplasia (BPH): Post-voiding Residual (PVR) Urinary Volume</title>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Post Residual Volume (PVR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="44"/>
                    <measurement group_id="O2" value="48" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month Post Residual Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="36"/>
                    <measurement group_id="O2" value="41" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month Post Residual Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="45"/>
                    <measurement group_id="O2" value="32" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hormone Levels: Total Testosterone, Free Testosterone, and Dihydrotestosterone(DHT), Dehydroepiandrosterone(DHEA), and Androstenedione.</title>
        <time_frame>Baseline, 3-months, 6-months</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Gel + Oral Placebo</title>
            <description>Testosterone 1% topical gel 7.5g daily + placebo dutasteride pill orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Gel + Oral Dutasteride</title>
            <description>Testosterone 1% topical gel 7.5g daily + dutasteride 0.5 mg orally daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hormone Levels: Total Testosterone, Free Testosterone, and Dihydrotestosterone(DHT), Dehydroepiandrosterone(DHEA), and Androstenedione.</title>
          <population>per protocol</population>
          <units>ng/ dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total testosterone, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" spread="109"/>
                    <measurement group_id="O2" value="213" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total testosterone, month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494" spread="331"/>
                    <measurement group_id="O2" value="525" spread="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total testosterone, month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481" spread="329"/>
                    <measurement group_id="O2" value="534" spread="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free testosterone, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.0"/>
                    <measurement group_id="O2" value="4.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free testosterone, month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="6.8"/>
                    <measurement group_id="O2" value="12.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free testosterone, month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="11.1"/>
                    <measurement group_id="O2" value="12.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydrotestosterone (DHT), baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="94"/>
                    <measurement group_id="O2" value="28" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydrotestosterone (DHT), month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" spread="120"/>
                    <measurement group_id="O2" value="16" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydrotestosterone (DHT), month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="87"/>
                    <measurement group_id="O2" value="12" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydroepiandrosterone (DHEA), baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="42"/>
                    <measurement group_id="O2" value="99" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydroepiandrosterone (DHEA), month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="92"/>
                    <measurement group_id="O2" value="109" spread="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydroepiandrosterone (DHEA), month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" spread="86"/>
                    <measurement group_id="O2" value="111" spread="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="21"/>
                    <measurement group_id="O2" value="47" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione, month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="72"/>
                    <measurement group_id="O2" value="140" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione, month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="57"/>
                    <measurement group_id="O2" value="123" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years. The study was conducted from March 2005 - March 2009.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Testosterone Gel + Oral Placebo</title>
          <description>Testosterone 1% topical gel 7.5g daily + placebo dutasteride pill orally daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Testosterone Gel + Oral Dutasteride</title>
          <description>Testosterone 1% topical gel 7.5g daily + dutasteride 0.5 mg orally daily for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>death from myocardial infarction</sub_title>
                <description>Subject had history of cardiovascular disease prior to randomization and normal hematocrit. Subject died during month 6.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>non-ST segment myocardial infarction</sub_title>
                <description>Subject had history of cardiovascular disease prior to randomization and normal hematocrit. Adverse event occurred during month 4.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated hematocrit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>exacerbation of pre-existing colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>mild breast tenderness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>increase in prostate specific antigen (PSA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ezcema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <description>transient rash at gel application site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alvin M. Matsumoto, MD</name_or_title>
      <organization>VA Puget Sound Health Care System</organization>
      <phone>(206) 764-2760</phone>
      <email>alvin.matsumoto@med.va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

